Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Background: Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties. The MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study was devised to evaluate the safety, tolerability, and activity of autologous MSCs derived from bone marrow and infused intravenously in patients with active multiple sclerosis. Methods: MESEMS is a randomised phase 2 trial done at 15 sites in nine countries. Patients (aged 18–50 years) with active relapsing-remitting or progressive multiple sclerosis were included if they had a disease duration of 2–15 years since onset of multiple sclerosis and an Expanded Disability Status Scale score of 2·5–6·5. Patients were randomly assigned (1:1), according to a crossover design, to receive a single intravenous dose of autologous bone marrow-derived MSCs followed by placebo at week 24, or to receive placebo followed by autologous MSCs at week 24, with a follow-up visit at week 48. Primary objectives were to test safety and activity of MSC treatment. The primary safety endpoint was to assess the number and severity of adverse events within each treatment arm. The primary efficacy endpoint was the number of gadolinium-enhancing lesions (GELs) counted over week 4, 12, and 24 compared between treatment groups. The primary efficacy endpoint was assessed in the full analyis set, after all participants completed the week 24 visit. Efficacy endpoints were evaluated using a predefined statistical testing procedure. Safety was monitored throughout the study by recording vital signs and adverse events at each visit. Findings: From July 16, 2012, until July 31, 2019, 144 patients were randomly assigned to first receive early intravenous infusion of autologous bone marrow-derived MSCs (n=69) or placebo (n=75). MSC treatment did not meet the primary endpoint of efficacy on the total number of GELs accumulated from baseline to week 24 (rate ratio [RR] 0·94, 95% CI 0·58–1·50; p=0·78). 213 adverse events were recorded, similarly distributed between groups (93 cases recorded in 35 [51%] of 69 patients treated first with MSCs vs 120 cases in 42 [56%] of 75 patients infused first with placebo). The most frequent adverse events reported were infection and infestations, with a total of 54 (25%) of 213 adverse events (18 [19%] of 93 in the early-MSC group and 36 [30%] of 120 in the delayed-MSC group). Nine serious adverse events were reported in seven patients treated with placebo versus none in the MSC group. All serious adverse events were considered to be unrelated to the treatment infusion. No deaths were reported during the study. Interpretation: Bone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on GELs, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24. Thus, this study does not support the use of bone marrow-derived MSCs to treat active multiple sclerosis. Further studies should address the effect of MSCs on parameters related to tissue repair. Funding: Fondazione Italiana Sclerosi Multipla (FISM), the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the Multiple Sclerosis International Federation (MSIF) for centralised activities. Individual trials participating in the MESEMS network are funded by the following agencies: FISM and Compagnia di San Paolo (Italy); The Danish Multiple Sclerosis Society, The Toyota Foundation, and Danish Blood Donors’ Research Foundation (Denmark); the Spanish Health Research Institute Carlos 3 and the Andalusian Public Foundation Progreso y Salud (Spain); the Royan Institute for Stem Cell Biology and Technology (Iran); the Spinal Cord Injury and Tissue Regeneration Centre Salzburg, Paracelsus Medical University, and Salzburg (Austria); the Fondation pour l'aide à la recherche sur la sclérose en plaques (ARSEP), French Muscular Dystrophy Association (AFM)-Telethon (France); the UK Multiple Sclerosis Society and the UK Stem Cell Foundation (UK); and the Multiple Sclerosis Society of Canada and The Multiple Sclerosis Scientific Research Foundation and Research Manitoba (Canada).
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | The Lancet Neurology |
| Vol/bind | 20 |
| Udgave nummer | 11 |
| Sider (fra-til) | 917-929 |
| Antal sider | 13 |
| ISSN | 1474-4422 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
We acknowledge all the participants of the trial, the investigators and the members of the Independent Data Safety Monitoring Committee. We thank the funding bodies Fondazione Italiana Sclerosi Multipla, the European Committee for Treatment and Research in Multiple Sclerosis, the Multiple Sclerosis International Federation, Compagnia di San Paolo, the Danish Multiple Sclerosis Society, Toyota Foundation, the Danish Blood Donors’ Research Foundation, Spanish Health Research Institute Carlos 3, Foundacion Progreso y Salud, the Royan Institute, the Spinal Cord Injury and Tissue Regeneration Centre, Fondation pour l’aide à la recherche sur la sclérose en plaques (ARSEP), French Muscular Dystrophy Association (AFM)-Telethon, the UK Multiple Sclerosis Society, the UK Stem Cell Foundation, the Multiple Sclerosis Society of Canada, the Multiple Sclerosis Scientific Research Foundation, and Research Manitoba. Trial registration numbers were as follows: in Andalusia, NCT01745783 ; Badalona, NCT02035514 ; EudraCT, 2010–024081–21; Canada, ClinicalTrials.gov , NCT02239393 ; Copenhagen, EudraCT, 2012–000518-13; Italy, EudraCT, 2011–001295-19 and NCT01854957 ; London, EudraCT, 2012–002357-35 and NCT01606215 ; Salzburg, EudraCT, 2015–000137-78; Stockholm, NCT01730547 ; and Toulouse, NCT02403947 .
Funding Information:
AU received funding for research by Fondazione Italiana Sclerosi Multipla and Compagnia di San Paolo. AL has received personal compensation from Novartis, Sanofi Genzyme, Biogen, Merck, and Roche for public speaking and advisory boards. AL received funding for research by Fondazione Italiana Sclerosi Multipla, the Italian Ministry of Health, and the Italian Ministry of University. MAB reports personal fees from Sanofi Genzyme, Biogen, Merck, Novartis, Bristol-Myers Squibb, Roche and non-financial support from Biogen, Roche and Genzyme. LB has received travel grants from Sanofi Genzyme, and Biogen and has received personal compensation for public speaking and advisory boards for Genzyme, Sanofi, Biogen, Novartis, and Merck. LB has grants from Swedish medical research foundation, the Brain foundation, Novonordisk Foundation, the Stockholm Council, and Karolinska Institutet. JM has received grant funding from Research Manitoba, The Multiple Sclerosis Society of Canada, The Multiple Sclerosis Scientific Research Foundation, and Roche Canada. SMN has received speaker honoraria from Biogen, Bayer, Genzyme, Merck Serono, Novartis, Sanofi, Abidipharma, Zist Daru Danesh, and Actoverco. RSO is now a full-time employee at Genmab but worked at the Copenhagen University Hospital Rigshospitalet and declared no conflict of interest while the trial was ongoing. JS has received personal compensation for serving on scientific advisory boards or receiving speaker honoraria for Alexion, Celgene, Biogen, Merck, Novartis, and Roche. PSS has received personal compensation for serving on scientific advisory boards, steering committees, and independent data-monitoring committees or has received speaker honoraria for Biogen, Merck, Novartis, TEVA, and Celgene. MPS has received consultancy fees from Teva Pharmaceuticals, Biogen, Novartis, Roche, Merck, Sanofi, Celgene, GeNeuro, Meddey, and Immunic. JTW has received personal compensation for advisory boards of Actelion, Bayer, Biogen, Celgene, Genzyme-Sanofi, Idorsia, InmuneBio, Novartis, and Roche. MSF reported receiving honoraria or consulting fees from Actelion, Bayer, Biogen, Chugai, EMD Canada, Merck Serono, Novartis, Roche, Sanofi, and Teva Canada Innovation, he also served as a member of an advisory board, board of directors, or other similar group for Actelion, Bayer, Biogen, Merck Serono, Novartis, Opexa, Roche, and Sanofi, and participated in the speakers bureau for Sanofi. All other authors declare no competing interests.
Funding Information:
We acknowledge all the participants of the trial, the investigators and the members of the Independent Data Safety Monitoring Committee. We thank the funding bodies Fondazione Italiana Sclerosi Multipla, the European Committee for Treatment and Research in Multiple Sclerosis, the Multiple Sclerosis International Federation, Compagnia di San Paolo, the Danish Multiple Sclerosis Society, Toyota Foundation, the Danish Blood Donors? Research Foundation, Spanish Health Research Institute Carlos 3, Foundacion Progreso y Salud, the Royan Institute, the Spinal Cord Injury and Tissue Regeneration Centre, Fondation pour l'aide ? la recherche sur la scl?rose en plaques (ARSEP), French Muscular Dystrophy Association (AFM)-Telethon, the UK Multiple Sclerosis Society, the UK Stem Cell Foundation, the Multiple Sclerosis Society of Canada, the Multiple Sclerosis Scientific Research Foundation, and Research Manitoba. Trial registration numbers were as follows: in Andalusia, NCT01745783; Badalona, NCT02035514; EudraCT, 2010?024081?21; Canada, ClinicalTrials.gov, NCT02239393; Copenhagen, EudraCT, 2012?000518-13; Italy, EudraCT, 2011?001295-19 and NCT01854957; London, EudraCT, 2012?002357-35 and NCT01606215; Salzburg, EudraCT, 2015?000137-78; Stockholm, NCT01730547; and Toulouse, NCT02403947.
Publisher Copyright:
© 2021 Elsevier Ltd
ID: 286083146